Skip to Primary Navigation

Skip to main content

ICER report finds rising drug launch prices and persistent barriers

A photo of a small white bowl with various prescription drug pills and capsules resting on top of one, five, and ten dollar bills.
Photo: Francis Dean/Corbis via Getty Images

Kevin Kinsella

1 min read

Research links higher launch prices with ongoing access challenges, highlighting coverage restrictions and affordability concerns for patients.

Prescription drug launch prices continued to rise between 2022 and 2025 while many patients faced significant hurdles accessing newly approved therapies, according to new research from the Institute for Clinical and Economic Review (ICER).

The 2026 Launch Price and Access Report examined launch pricing trends for newly approved drugs and

, , , , , ,

Get full access, free for a month

Start your 28-day free trial to continue reading and accessall content on GRIP – no payment details required.

Start free trial
Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience